Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic Esophagitis [Yahoo! Finance]
Eupraxia Pharmaceuticals Inc. (EPRX)
Company Research
Source: Yahoo! Finance
The data is important because it is from one of the two doses that are being studied in the placebo-controlled Phase 2b portion of the study. Patients in the highest dose cohort (n=3) had an average reduction of 4 points in their symptom scores compared to baseline (as measured by SDI, where a 3 point reduction is clinical remission). Across dose cohorts 4-9, the decrease in symptom response is the highest at 24 weeks, compared to earlier timepoints. This underlines the value of continuous and steady steroid exposure to reduce inflammation early and fibrosis over time in EoE patients. EP-104GI continues to be well tolerated by patients receiving the drug; 31 patients have been treated in the Phase1b/2a study and over 220 patient-months of follow-up have been reported with no Serious Adverse Events ("SAEs"). There have been no cases of oropharyngeal candidiasis, a commonly reported adverse event with the oral delivery of steroids. VICTORIA, British Columbia, March 17, 2026 (GLO
Show less
Read more
Impact Snapshot
Event Time:
EPRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EPRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EPRX alerts
High impacting Eupraxia Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
EPRX
News
- Eupraxia Pharmaceuticals (EPRX) was downgraded by Zacks Research from "hold" to "strong sell".MarketBeat
- Eupraxia Pharmaceuticals (EPRX) had its price target lowered by HC Wainwright from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Yahoo Finance [Yahoo! Finance]Yahoo! Finance
- Eupraxia Pharmaceuticals Reports Six-Month Symptom Data from the Highest Dose Cohort in its Ongoing Phase 1b/2a RESOLVE Trial in Eosinophilic EsophagitisGlobeNewswire
- Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial ResultsGlobeNewswire
EPRX
Sec Filings
- 3/17/26 - Form 6-K
- 3/16/26 - Form SCHEDULE
- 3/13/26 - Form 40-F
- EPRX's page on the SEC website